This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Stanford University School of Medicineled researchers have found that intensive bloodpressure (BP) control produces cardiovascular benefits and increases the risk of adverse events in people with chronic kidneydisease (CKD).
Research Highlights: A new study finds that up to 74% of participants with resistant or difficult-to-control high bloodpressure, including those with chronic kidneydisease, were able to improve control of their bloodpressure within 12 months after.
Akshay Desai, MD “Compared to placebo, a single injection of zilebesiran resulted in clinically meaningful reductions in bloodpressure at three months when added to commonly used antihypertensive treatments,” said Akshay Desai, MD, MPH , a cardiologist at Brigham and Women’s Hospital in Boston and a study coauthor. “In
Hypertension is a leading cause of morbidity and mortality worldwide and poses a major risk factor for cardiovascular diseases and chronic kidneydisease.
We do a terrible job of identifying and managing high bloodpressure. And we still do an awful job of identifying and managing high bloodpressure. As a risk factor for death, high bloodpressure is responsible for more deaths than any other risk factor, including smoking. What Is Normal BloodPressure?
High bloodpressure, also known as hypertension, is a common condition that affects millions of people worldwide. Understanding how high bloodpressure impacts your heart and learning to manage it can significantly reduce your risk of heart disease and improve your overall health. What Is High BloodPressure?
(MedPage Today) -- A computerized clinical decision support (CDS) tool for primary care helped lower bloodpressure (BP) in patients with chronic kidneydisease (CKD) and uncontrolled hypertension, a cluster-randomized trial found. When primary.
BACKGROUND:Intensive bloodpressure (BP) control in youth with chronic kidneydisease (CKD) slows progression, delaying the need for kidney replacement therapy (KRT). Hypertension, Ahead of Print. We compared this intervention to usual care in a hypothetical population of youth with mild-to-moderate CKD.
Mineralocorticoid excess commonly leads to hypertension (HTN) and kidneydisease. However, finerenone was particularly effective in reducing albuminuria and improving gene expression changes in podocytes and proximal tubule cells, even with an equivalent reduction in bloodpressure.
Keeping your bloodpressure in check is a good way to lower your risk of heart disease, stroke, and kidneydisease. So, you follow orders, take your prescribed medication, and proudly accept your doctor's praise when the bloodpressure cuff demonstrates continued success. Until it doesn't.
Classically, activation of the MR in the renal tubular epithelium is responsible for sodium retention and volume expansion, raising systemic bloodpressure.
AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce bloodpressure. mmHg in office systolic bloodpressure (oSBP) at six months when compared to control patients. Suman Pasupuleti, M.D.
Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidneydisease (ESKD) on dialysis. However, the evidence on the benefits of ARNI in HF patients with end-stage kidneydisease (ESKD) undergoing dialysis is limited.
milla1cf Fri, 06/28/2024 - 19:07 June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa , its flagship health equity initiative, to target a broader range of non-communicable diseases (NCDs), including chronic kidneydisease (CKD) as well as hypertension and cardiovascular disease.
BackgroundChronic kidneydisease (CKD) is closely associated with cardiovascular disease. Meanwhile, higher scores for blood glucose (odds ratio, for each 10‐point increase, 0.88 [95% CI, 0.87–0.90]) 0.90]) and bloodpressure (odds ratio, for each 10‐point increase, 0.92 [95% CI, 0.91–0.94])
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
Background:Dietary magnesium (Mg+2) deficiency has been linked to hypertension, chronic kidneydisease, and cardiovascular disease. High sodium intake and reduced dietary Mg+2consumption are associated with elevated bloodpressure.
Background Preeclampsia (PE) is associated with subsequent higher risk of cardiovascular and kidneydisease. Serum copeptin, as a proxy for vasopressin, and urinary uromodulin, were associated with PE physiopathology and kidney functional mass respectively.
BackgroundBoth nighttime systolic bloodpressure and pulse rate are associated with adverse outcomes in patients with chronic kidneydisease (CKD). However, nighttime double product (DP), which is the product of nighttime systolic bloodpressure and pulse rate, has not yet been investigated in this context.
Panelists discuss how chronic kidneydisease (CKD) and uncontrolled hypertension create a damaging cycle, in which hypertension accelerates kidney damage while declining kidney function makes bloodpressure harder to control.
Panelists discuss how poor medication adherence and comorbidities such as chronic kidneydisease (CKD) contribute to uncontrolled hypertension despite the availability of numerous treatment options, highlighting key challenges in achieving effective bloodpressure management.
Does a computerized clinical decision support (CDS) system based on behavioral economic principles and human-centered design lead to a decrease in systolic bloodpressure (SBP) in patients with chronic kidneydisease (CKD) and uncontrolled hypertension?
Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidneydisease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.
Introduction:Smoking is a well-known risk factor for atherosclerotic cardiovascular disease and kidney failure among patients with chronic kidneydisease (CKD). Circulation, Volume 150, Issue Suppl_1 , Page A4142036-A4142036, November 12, 2024. However, the association of former and current smoking status (vs.
BACKGROUND:Hypertension frequently accompanies chronic kidneydisease (CKD) as etiology and sequela. Hypertension, Volume 80, Issue 12 , Page 2533-2543, December 1, 2023. We defined CKD as a sustained estimated glomerular filtration rate value <60 mL/min per 1.73 m2or a urine albumin-to-creatinine ratio ≥30 mg/g.
Death from heart disease: 51% reduction in risk. High BloodPressure: 37% reduction in risk. KidneyDisease: 42% reduction in risk. Death from any cause: 53% reduction in risk. Cancer deaths: 43% reduction in risk. Heart Failure: 69% reduction in risk. Dementia: 64% reduction in risk. Let me be clear.
It is risk factor for cardiovascular disease, stroke and kidneydisease. Hence, this study aimed to assess bloodpressure (BP) self-monitoring practice and associated factors among adult hypertensive patients on follow-up in South Wollo Zone public hospitals, Northeast Ethiopia.
METHODS:The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing.
Patients with chronic kidneydisease (CKD) whose systolic bloodpressure (SBP), LDL-C and fasting blood glucose (FBG) were controlled to target levels experienced a similar number of primary outcome events as patients without CKD, according to a new study published in JACC.
Additionally, 10% of the global population suffers from chronic kidneydisease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. In the U.S.,
Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), blocking the mineralocorticoid receptor and its bloodpressure effects. Finerenone is already approved to reduce cardiovascular and kidneydisease risks in patients with type 2 diabetes-associated CKD, but not for HF.
Here, for example, plucked at random, is a reference to the latest NICE guidelines on the management of hypertension (high bloodpressure) in adults. In addition, there are links to formal risk assessment in cardiovascular disease. No, we the mighty, have told you what constitutes perfect care for raised bloodpressure.
BACKGROUND:Polycystic kidneydisease is the most common hereditary kidney disorder with early and frequent hypertension symptoms. Molecular analysis was performed through transcriptomic profiling and biochemical approaches.RESULTS:Bsg-deficient mice exhibited significantly elevated arterial bloodpressure.
The associations of microvascular disease states (defined by the presence of retinopathy, peripheral neuropathy or chronic kidneydisease), four modifiable arrhythmic risk factors (body mass index, smoking, systolic bloodpressure and glycosylated haemoglobin) and their joint associations with incident arrhythmias were examined.
Results Baseline characteristics revealed significant differences between NUA and HUA groups, with the latter exhibiting a higher prevalence of males, chronic kidneydisease (CKD) and elevated levels of various biomarkers. in the NUA group. to 1.72, p=0.001).
Patients in VERISEC were older and had more comorbidities (diabetes, advanced chronic kidneydisease) compared to VICTORIA, with 20% having an estimated glomerular filtration rate below 30ml/min. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7) 7,054.0)] pg/ml.
This article will review the origins of elevated bloodpressure from when it was first appreciated in 2600 BC to its most recent emerging treatments. But really, it has only been since well after World War II that hypertension has finally been appreciated as the cause of so much heart, stroke, and kidneydisease.
Susceptibility MMD genes, including ring finger protein 213/mysterin andGUCY1A3, have also been linked to extracranial vascular disease and increased systolic bloodpressure. Bloodpressure measurements and antihypertensive agent use were recorded pre‐ and postoperatively. After a mean follow‐up of 34.3±18.1
a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidneydisease (CKD) and other diseases, hasannounced that the U.S. tim.hodson Wed, 01/08/2025 - 14:11 Jan. 8, 2025 Mineralys Therapeutics, Inc.,
Introduction:Blood pressure targets for the elderly are still controversial, there is a lack of certainty about the benefit and safety of targeting ≤ 130mmHg systolic bloodpressure. of patients had cardiovascular disease, 10.9% chronic kidneydisease. diabetes, and 15.5%
Among those ages 65 and older, nearly 50% who underwent limb amputation died within one year after surgery, according to the 2024 Heart Disease and Stroke Statistics: A Report of U.S. and Global Data From the American Heart Association. All patients with PAD should be treated with high-intensity statin therapy.
Consistent recent data from randomized controlled trials show that potassium-enriched, sodium-reduced salt substitutes are an effective option for improving consumption levels and reducing bloodpressure and the rates of cardiovascular events and deaths. Yet, salt substitutes are inconsistently recommended and rarely used.
Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among Results:Among 5002 (projected to 34.0
Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidneydisease and heart failure. Circulation, Volume 150, Issue Suppl_1 , Page A4121215-A4121215, November 12, 2024.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content